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C-Reactive Protein and
ST-Segment Elevation
Myocardial Infarction
Discordance*
C. Richard Conti, MD
Gainesville, Florida
In this issue of the Journal, Cristell et al. (1) performed a
ovel study to test the prevalence of elevated circulating
igh-sensitivity C-reactive protein (CRP) immediately
rior to ST-segment elevation myocardial infarction
STEMI). This was accomplished in 887 patients with
TEMI as well as 887 control patients from urban areas in
regions: Italy, Scotland, and China.
The investigators indicate that the diagnosis of infarction
as documented unequivocally in all by the presence of
T-segment elevation on presentation and by subsequent
eak creatine phosphokinase elevation. Many STEMI pa-
ients successfully underwent reperfusion. Blood samples
ere obtained up to 6 h from symptom onset prior to
eperfusion. The methods of collection of blood seemed
ppropriate, and all samples were shipped in dry ice to a core
aboratory in Milan, Italy.
See page 2654
Symptom time was the least in Scottish patients, and
troponin I measurements were also less in the Scottish
patients than in the Italian and Chinese patients.
Most of the patients in this study had not received any
antiangina, antilipid, or antiplatelet therapy prior to entry
into the study.
The investigators restricted inclusion criteria in order to
try to select a phenotypically homogeneous group. However,
this was not the case, because results indicate a large scatter
of CRP values among the patients studied. The overlap of
CRP values with those of control subjects was great and was
not significantly related to the risk factor levels examined.
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disclose.Median CRP values were significantly higher in patients
than in control subjects, but the overlap was such that 37%
of control subjects had values greater than 2 mg/l, and there
was a wide overlap of values as shown in the Cristell et al.
Figure 2 (1) for both high-sensitivity CRP as well as
interleukin-6.
The investigators make the point that their observations
are indicative of pre-infarction levels for CRP. Because
others have reported (2) that CRP levels begin to increase
about 6 h after infarction onset, it seems to me that this
would be about the same time as other cardiac markers such
as creatine kinase-myocardial band and troponin I, both of
which would rise as well.
The investigators found no difference in the average CRP
levels in patients sampled at 2 h, 2 to 4 h, and 4 to 6 h
from the onset of symptoms. In this regard, it is important
to point out that the timing of symptom onset in the human
may not necessarily be the same as the timing of the
infarction onset. The first indication for a STEMI comes
generally with the electrocardiogram (ECG) taken in the
emergency department or in the emergency vehicle and not
at the time of symptom onset.
Perhaps one can identify patients whose myocardial
infarction occurred recently: on or just prior to admission
versus those who infarcted somewhat earlier by assessing the
troponin I level. If the troponin I was abnormal on admis-
sion, the infarction probably would have occurred at the
time of or near the time of the onset of symptoms, and if the
troponin I was normal on admission, it could have occurred
at a time closer to the initial ECG with ST-segment
elevation. The Cristell et al. Table 2 (1) compares symptom
time in minutes to troponin I in ng/ml and peak creatine
phosphokinase units/l. Although these are average values,
they do not reflect the initial troponin on admission to
hospital or entry into the study, nor do they reflect initial
creatine phosphokinase values. It might be instructive to
have a scatter plot as in Figure 2 in Cristell et al. (1), in
which all the individual data points for high-sensitivity
CRP taken in the various countries are plotted versus the
troponin I measured at the time of ECG diagnosis of
STEMI.
In my opinion, troponin I defines the timing of the acute
myocardial infarction. For example, if it is normal, the
STEMI may have been very recent, whereas if the troponin
I was elevated at the time of the abnormal ECG, the infarct
was not recent. What is not known, in my view, is what the
relationship is of the CRP under these circumstances. For
example, was high-sensitivity CRP 2 seen more often in
patients with normal troponin I on admission compared to
high-sensitivity CRP 2?
Average CRP levels were similar in patients with average
troponin I 0.2 and 0.2. Although 52% of patients had
an initial admission troponin I of 0.2 ng/ml, 48% had
elevation of the troponin I to an average of 2.09 ng/ml. CRP
levels were similar in patients with troponin I 0.2 and
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December 13/20, 2011:2662–3 CRP and STEMI Discordance0.2. Because of the wide scatter of the data, measurements
of CRP prior to STEMI do not adhere to the concept of
“one size fits all.” This was not a homogeneous population.
Although statistical significance was found in this study,
and one can prognosticate in large populations, this may not
have any clinical relevance for the individual because of the
overlap of data.
The investigators indicate that at present we have no
plausible explanation for the finding of high-sensitivity
CRP 2 mg/l in 41% of STEMI cases for all 3 ethnic
roups considered. Is it possible that the myocardial infarc-
ion just occurred at the time of arrival of the patient in the
mergency department, rather than at the time of the onset
f symptoms? In other words, in the emergency department,
CG changes of ST-segment elevation do not mean myo-
ardial infarction occurred at that time.
My take on this paper is that each patient is an individual
nd thus clinical trials cannot be applied to every patient
ecause clinical trials provide average results and, as the
nvestigators point out, “one size does not fit all.” As a
linician, it is obvious to me that patient-specific therapy
till requires clinical judgment, and clinical judgment is
ased on not just 1 factor, but on several factors, making it
composite of clinical trial results, experience, intuition,
nd common sense.
To summarize, in the individual patient, prognostication is
n educated guess, nothing more. Because prognostic informa-
ion on medical conditions is based on population studies, for
ny given condition, a certain percentage will have a major
dverse cardiac event and others will be free of major adverse
ardiac events. Thus, when it comes to the individual patient,
here are no percentages other than 0 or 100.
Clinical trials, epidemiologic studies, and registries areood but not perfect. They do not explain all the clinicaloutcomes (i.e., the outliers), and thus there is a great deal to
learn from these outliers and unusual clinical cases.
The critical question that needs to be answered in the
future is: “What percentage of patients develop an acute
myocardial infarction in spite of normal high-sensitivity
CRP levels?” These investigators are planning to take a very
hard look at the “outliers,” that is, those control subjects
who had elevated high-sensitivity CRP and those STEMI
patients who had normal high-sensitivity CRP.
Future studies will involve biologic and genetic charac-
terization of these 2 extreme groups. From what I gather of
this investigation, the investigators will eventually focus on
the reasons for the outcomes in the patients who are
outliers—a difficult challenge, and I wish them well because
I believe these types of observations will advance our
understanding of prognosis of the individual. Overall, the
authors are to be congratulated for taking a different look at
data collection while making the point that average data
reported in any clinical trial do not represent many of the
outliers.
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